Seongseok Yun, MD, PhD

Cancer Focus:
Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia

Dr. Yun recently completed a Hematology and Medical Oncology Fellowship at Moffitt Cancer Center.  Dr. Yun’s clinical interests include management of patients with hematologic malignancies with a focus on Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).  As a physician-scientist with clinical and basic research expertise in hematologic malignancies, his scientific career is dedicated to understanding and targeting molecular circuits that contribute to the development, maintenance, drug-induced cytotoxicity and resistance of Acute Leukemia.

Education & Training

Fellowship:

• Moffitt Cancer Center - Hematology and Oncology

Residency:

• University of Arizona Medical Center -

Medical School:

• Seoul National University, College of Medicine - MD

• Xie Z, Al Ali N, Zhang L, Papenhausen P, Volpe VO, Chan O, Kuykendall A, Yun S, Walker A, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji RS. Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. Blood Neoplasia. 2025 May.2(2):100062. Pubmedid: 40453136. Pmcid: PMC12067887.
• Komrokji Z, Ali NA, Xie Z, Chan O, Yun S, Walker A, Lancet J, Kuykendall A, Sallman D, Padron E, Komrokji RS. Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML). Leuk Res. 2025 Mar.150:107662. Pubmedid: 39921921.
• Komrokji RS, Ammad-Ud-Din M, Ali NHA, Xie Z, Chan O, Kuykendall AT, Yun S, Walker AR, Lancet J, Padron E, Sallman DA. Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival. Clin Lymphoma Myeloma Leuk. 2025 Jul.25(7):e487-e490. Pubmedid: 40113545.
• Chan O, Al Ali NH, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini MO, Song J, Yun S, Talati C, Kuykendall AT, Padron E, Walker AR, Roboz GJ, Desai P, Sallman DA, Sweet KL, Komrokji RS, Lancet JE. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024 Mar.8(5):1075-1083. Pubmedid: 38170740. Pmcid: PMC10907389.
• Vincelette ND, Yu X, Kuykendall AT, Moon J, Su S, Cheng CH, Sammut R, Razabdouski TN, Nguyen HV, Eksioglu EA, Chan O, Al Ali N, Patel PC, Lee DH, Nakanishi S, Ferreira RB, Hyjek E, Mo Q, Cory S, Lawrence HR, Zhang L, Murphy DJ, Komrokji RS, Lee D, Kaufmann SH, Cleveland JL, Yun S. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood Cancer Discov. 2024 Jul.5(4):276-297. Pubmedid: 38713018. Pmcid: PMC11215389.
• Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clin Lymphoma Myeloma Leuk. 2024 Jul.24(7):459-467. Pubmedid: 38548563.
• Horvat NP, Abdallah EF, Xie Z, Al Ali N, Yun S, Walker A, Padron E, Sallman D, Chan O, Lancet J, Komrokji R, Kuykendall AT. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024 Jan.103(1):117-123. Pubmedid: 38030891.
• Yun S, Cleveland JL. Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple Myeloma. Blood Cancer Discov. 2024 Jan.5(1):5-7. Pubmedid: 38085608. Pmcid: PMC10772544.
• Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. Cancer Discov. 2024 Dec.14(12):2509-2531. Pubmedid: 39189614. Pmcid: PMC11611684.
• Mo Q, Yun S, Sallman DA, Vincelette ND, Peng G, Zhang L, Lancet JE, Padron E. Integrative molecular subtypes of acute myeloid leukemia. Blood Cancer J. 2023 May.13(1):71. Pubmedid: 37156780. Pmcid: PMC10167212.
• Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
• Zhang L, Shah B, Zhang Y, Tashkandi H, Xiao W, Fernandez-Pol S, Vergara-Lluri M, Hussaini M, Song J, Lancet J, Moscinski L, Yun S, Lu CM, Medeiros LJ, Tang G. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review. Hum Pathol. 2023 Jun.136:1-15. Pubmedid: 36958463.
• Jordan AI, Zhang L, Yun S. Nonhealing Cutaneous Ulcers in a Patient With Myelodysplastic Syndrome. JAMA Oncol. 2023 Jun.9(6):860-861. Pubmedid: 37052896.
• Patel PC, Ball S, Jain AG, Wang C, Hussaini MO, Aguirre LE, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet JE, Komrokji RS, Sallman DA. Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. Am J Hematol. 2023 Dec.98(12):E360-E363. Pubmedid: 37705256.
• Kuykendall AT, Mo Q, Sallman DA, Ali NA, Chan O, Yun S, Sweet KL, Padron E, Lancet JE, Komrokji RS. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022 Oct.128(19):3495-3501. Pubmedid: 35942592.
• Horvat NP, Logothetis CN, Zhang L, Yun S, Sweet K. Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia. Cureus. 2022 Mar.14(3):e23618. Pubmedid: 35505715. Pmcid: PMC9053382.
• Castillo Tokumori F, Al Ali N, Chan O, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e521-e525. Pubmedid: 35241387.
• Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
• Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, McGraw KL, Moon J, Murphy DJ, Ballabio A, Kaufmann SH, Berglund AE, Cleveland JL. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021 Mar.2(2):162-185. Pubmedid: 33860275. Pmcid: PMC8043621.
• Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: 33591325. Pmcid: PMC7903224.
• Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. MYC overexpression is associated with an early disease progression from MDS to AML. Leuk Res. 2021 Dec.111:106733. Pubmedid: 34749168. Pmcid: PMC8643343.
• Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021 Apr.35(4):1145-1155. Pubmedid: 32728186. Pmcid: PMC7854836.
• Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Ali NA, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, Sallman DA, Cluzeau T. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Eur J Haematol. 2020 May.104(5):488-498. Pubmedid: 31990086.
• Yun S, Chan O, Kerr D, Vincelette ND, Idrees A, Mo Q, Sweet K, Lancet JE, Kharfan-Dabaja MA, Zhang L, Sokol L. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv. 2020 Jul.4(14):3435-3442. Pubmedid: 32722779. Pmcid: PMC7391135.
• Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: 32778513.
• Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I. Response to Yang, Shi, Wang et al. J Natl Cancer Inst. 2020 Apr.112(4):428. Pubmedid: 31424546. Pmcid: PMC7156932.
• Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: 31357093. Pmcid: PMC7375354.
• Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I. Response to Katona et al. J Natl Cancer Inst. 2019 May.111(5):524-525. Pubmedid: 30715401.
• Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J, Maloney DG. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019 Mar.12(3):195-205. Pubmedid: 30793644.
• Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J. 2019 Jul.17:13. Pubmedid: 31303864. Pmcid: PMC6604148.
• Yun S, Sokol L, Zhang L. Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome. JAMA Oncol. 2018 Sep.4(9):1281-1282. Pubmedid: 29800978.
• Yun S, Vincelette ND. Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med. 2018 Sep.379(12):1186. Pubmedid: 30260155.
• Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018 Nov.110(11):1178-1189. Pubmedid: 30380096.
• Yun S, Zhang L, Patel MR, Knepper TC, Chavez JC, Pinilla-Ibarz J. Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia. Blood. 2018 Mar.131(11):1258-1261. Pubmedid: 29437555.
• Tenneti P, Zahid U, Iftikhar A, Yun S, Sohail A, Warraich Z, Anwer F. Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review. Sarcoma. 2018 Jun.2018:2640674. Pubmedid: 29973774. Pmcid: PMC6008812.
• Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH. Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). J Drug Assess. 2018 Jul.7(1):51-53. Pubmedid: 30034924. Pmcid: PMC6052412.
• Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, Baz RC, Anwer F. Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clin Lymphoma Myeloma Leuk. 2017 May.17(5):252-262. Pubmedid: 28366781. Pmcid: PMC5413391.
• Abraham I, Yami MA, Yun S, Kim HJ, Vincelette ND, McBride A, MacDonald K. Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies. Leuk Res. 2017 Jun.57:104-108. Pubmedid: 28343141.
• Yun S, Vincelette ND, Acharya U, Abraham I. Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials. Clin Lymphoma Myeloma Leuk. 2017 Jan.17(1):31-37.e13. Pubmedid: 27780690.
• Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F. Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. Crit Rev Oncol Hematol. 2017 Jan.109:42-50. Pubmedid: 28010897. Pmcid: PMC5218629.
• Yun S, Khoubyari R, Abraham I. Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effects. JAMA Oncol. 2016 Oct.3(2):279. Pubmedid: 27787557.
• Yun S, Acharya U. Waxing and Waning Pruritic Cutaneous Lesions Refractory to Antibiotic Treatment. JAMA Oncol. 2016 Nov.2(11):1501-1502. Pubmedid: 27467706.
• Yun S, Vincelette ND, Segar JM, Dong Y, Shen Y, Kim DW, Abraham I. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. Clin Lymphoma Myeloma Leuk. 2016 Jun.16(6):e85-e94. Pubmedid: 27101984.
• Yun S, Vincelette ND, Abraham I. Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia. JAMA Oncol. 2016 Jun.2(6):828-829. Pubmedid: 27281623.
• Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin Epigenetics. 2016 Jun.8:68. Pubmedid: 27307795. Pmcid: PMC4908810.
• Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH. 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood. 2016 Jun.127(22):2711-2722. Pubmedid: 26917778. Pmcid: PMC4891953.
• Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med. 2016 Jul.5(7):1481-1491. Pubmedid: 27167347. Pmcid: PMC4867662.
• Alcharakh M, Yun S, Dong Y, Vincelette ND, Daud M, Manzoor S, Riaz IB, Anwer F. Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. Immunotherapy. 2016 Jul.8(8):847-852. Pubmedid: 27381683.
• Yun S, Vincelette ND. Skin Lesions and Recurrent Fever in Acute Myeloid Leukemia Patient Treated With Allogeneic Stem Cell Transplant. JAMA Oncol. 2016 Dec.2(12):1649-1650. Pubmedid: 27583691.
• Yun S, Vincelette ND, Abraham I, Puvvada S, Anwer F. Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. Acta Haematol. 2016 Dec.136(4):244-255. Pubmedid: 27802434.
• Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y, Yun S, Abraham I, Erstad B. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood. 2016 Dec.128(26):3043-3051. Pubmedid: 27793877. Pmcid: PMC6863170.
• Shen Y, Dong YM, Lu Q, Xu J, Wu YT, Yun SS, Ren ML. Phenolic environmental estrogens in urine and blood plasma from women with uterine leiomyoma: Epidemiological survey. J Obstet Gynaecol Res. 2016 Apr.42(4):440-445. Pubmedid: 26842765.
• Yun S, Vincelette ND, Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J. 2015 Nov.91(1081):627-633. Pubmedid: 26399268.
• Yun S, Vincelette ND. Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis. Crit Rev Oncol Hematol. 2015 Jul.95(1):12-25. Pubmedid: 25737209.
• Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015 Jul.2015:583451. Pubmedid: 26180646. Pmcid: PMC4477130.
• Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015 Apr.2015:794842. Pubmedid: 25918658. Pmcid: PMC4396732.
• Yun S, Ko J, Vincelette ND, Anwer F. Lymphomatous orbital infiltration and vision loss in diffuse large B-cell lymphoma. BMJ Case Rep. 2014 May.2014. Pubmedid: 24872494. Pmcid: PMC4039974.
• Yun S, Howe LN, Afshar S, Jahan K. Concurrent diffuse alveolar haemorrhage and venous thromboembolism in p-ANCA associated vasculitis treated with rituximab. BMJ Case Rep. 2014 Jun.2014. Pubmedid: 24916986. Pmcid: PMC4054105.
• Yun S, Walker CN, Vincelette ND, Anwer F. Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. BMJ Case Rep. 2014 Jun.2014. Pubmedid: 24913086. Pmcid: PMC4054106.
• Yun S, Vincelette ND, Phan T, Anwer F. Spontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma. BMJ Case Rep. 2014 Jul.2014. Pubmedid: 25028407. Pmcid: PMC4112310.
• Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 2014 Jan.99(1):60-69. Pubmedid: 23996484. Pmcid: PMC4007940.
• Taverna J, Nair A, Yun S, Paulson S, Schatz JH, Persky D, Fuchs D, Puvvada S. A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature. Case Rep Hematol. 2014 Dec.2014:145129. Pubmedid: 25478252. Pmcid: PMC4249607.
• Taverna JA, Babiker HM, Yun S, Bishop MC, Lau-Braunhut S, Meyer PN, Enzler T. The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res. 2014 Dec.2(1):23. Pubmedid: 25635225. Pmcid: PMC4310203.
• Yun S, Braunhut BL, Walker CN, Bhati W, Sussman AN, Anwer F. Nephrotic syndrome secondary to proliferative glomerulonephritis with monoclonal immunoglobulin deposits of lambda light chain. Case Rep Nephrol. 2014 Aug.2014:164694. Pubmedid: 25136462. Pmcid: PMC4129672.
• Yun S, Taverna JA, Puvvada SD, Anwer F. NK/T-cell non-Hodgkin's lymphoma with secondary haemophagocytic lymphohistiocytosis treated with matched unrelated donor allogeneic stem cell transplant. BMJ Case Rep. 2014 Aug.2014. Pubmedid: 25123574. Pmcid: PMC4139541.
• Yun S, Anwer F, Vincelette ND. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. BMJ Case Rep. 2014 Apr.2014. Pubmedid: 24810451. Pmcid: PMC3992554.
• Gupta M, Hendrickson AE, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, Flatten KS, Hess AD, Smith BD, Karp JE, Barr S, Witzig TE, Kaufmann SH. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2012 Jan.119(2):476-487. Pubmedid: 22080480. Pmcid: PMC3257013.

• Title: Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in AML
  Award Number:
  Sponsor: American Society of Clinical Oncology (ASCO)
  Yun, S. (PD/PI)
• Title: MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis
  Award Number: 5R01CA280116-02
  Sponsor: National Cancer Institute (NCI)
  Yun, S. (PD/PI)